DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Navitoclax is an investigational drug.
There have been 15 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and Abbott.
There are one hundred and sixty-five US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Navitoclax
|A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm||AbbVie||Phase 1|
|A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis||AbbVie||Phase 2|
|A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia||AbbVie||Phase 1|
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Navitoclax||Start Trial||Substituted indole Mcl-1 inhibitors||Vanderbilt University (Nashville, TN)||Start Trial|
|Navitoclax||Start Trial||Antibody drug conjugates||Novartis AG (Basel, CH)||Start Trial|
|Navitoclax||Start Trial||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||Start Trial|
|Navitoclax||Start Trial||Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors||AbbVie Inc. (North Chicago, IL)||Start Trial|
|Navitoclax||Start Trial||Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders||Novartis AG (Basel, CH)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Navitoclax||European Patent Office||3038618||2033-08-28||Start Trial|
|Navitoclax||World Intellectual Property Organization (WIPO)||2015031608||2033-08-28||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|